Guerbet, Caisse Centrale de Réassurances, L’Occitane and Sopra Steria were among the backers for the life sciences-focused venture firm's BioMedTech fund.
France-based venture capital firm Truffle Capital has closed a €250m ($278m) fund that featured medical imaging technology producer Guerbet, reinsurer Caisse Centrale de Réassurances and digital services provider Sopra Steria as limited partners.
French investors provided 60% of the capital and also included cosmetics producer L’Occitane Group’s startup studio, Obratori, as well as financial services group BPCE and pension funds ProBTP and Agrica. Undisclosed family offices also contributed to the close.
Truffle Capital invests in life sciences technology developers, but…
